Boston Scientific Corporation growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +17.4%
EBITDA: +36.1%
EBIT: +42.7%
EPS: +74.0%
Free cash flow: +19.8%
Operating cash flow: +13.9%

Forward estimates

Revenue: +13.8%
EBITDA: -9.5%
EPS: +53.3%

Three-year CAGR

Revenue: +16.5%
EBITDA: +23.0%
EBIT: +29.6%
Net income: +60.5%
EPS: +63.5%
Free cash flow: +58.8%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.